Episodes
April 2023: Use of a PreEMPT model found that universal genetic screening for hypertrophic cardiomyopathy at birth would save lives but was unlikely to be cost-effective
Published 04/06/23
Published 03/07/23
March 2023: OXGR1 variants: novel candidate disease gene for kidney stone disease?
Published 03/07/23
February 2023: Diagnosing genetic developmental and epileptic encephalopathies in Africa
Published 02/03/23
February 2023: Diagnosing genetic developmental and epileptic encephalopathies in Africa
Published 02/03/23
January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey
Published 01/09/23
December 2022: Standardizing variant annotation
Published 12/02/22
November 2022: Disclosure of secondary findings from genomic testing in children
Published 11/04/22
October 2022: A points to consider statement of the ACMG
Published 10/04/22
September 2022: CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis
Published 09/02/22
August: Klinefelter Syndrome and XYY in males mostly unrecognized in a large biobank study
Published 08/01/22
July: Recommendations for next generation sequencing data reanalysis of unsolved cases with suspected Mendelian disorders: A systematic review and meta-analysis
Published 07/06/22
June: Harmonizing gene–disease evidence resources globally
Published 05/27/22
May: The Clinical Variant Analysis Tool: a systematic way to assess genomic testing results
Published 05/04/22
April: The positive economic impact of rapid genomic testing for critically ill infants and children
Published 04/08/22
March: Genome sequencing holds great potential to diagnose newborns with phenotypes suggestive of a genetic disorder. However, this technology has not been widely adopted for this population, and particularly not in newborns from underserved and low-income communities.
Published 03/09/22
February: Matchmaking is an increasingly important strategy to help link rare diseases to genetic variants. These tools allow clinicians and researchers to search across previously siloed databases, clinics, and laboratories and access data about the potential genetic underpinnings of undiagnosed rare diseases across international boundaries. But to date there hasn’t been much research on the user experience.
Published 02/03/22
January: When it comes to breast cancer, Non-Hispanic Black women have a 40% higher mortality rate than Non-Hispanic White women. Additionally, Non-Hispanic Black women have dramatically lower rates of uptake of genetic testing and then, if testing finds variants that would warrant such actions, undergoing prophylactic preventative surgeries.
Published 01/03/22
As cardiovascular disease has many known genetic components, a team of researchers at Baylor College of Medicine created a panel of genes associated with cardiovascular disease they call HeartCare. David Murdock, previously the assistant director of the clinical lab at Baylor College of Medicine’s Human Genome Sequencing Center and now a lab director at Invitae, states “we thought that by looking at genetic causes of cardiovascular disease in an adult population, that could really help us to...
Published 12/06/21
December: As cardiovascular disease has many known genetic components, a team of researchers at Baylor College of Medicine created a panel of genes associated with cardiovascular disease they call HeartCare. David Murdock, previously the assistant director of the clinical lab at Baylor College of Medicine’s Human Genome Sequencing Center and now a lab director at Invitae, states “we thought that by looking at genetic causes of cardiovascular disease in an adult population, that could really...
Published 12/01/21
November: Polygenic risk scores (PRS) can be an important tool in breast cancer patients to help stratify individuals into levels of disease risk. The clinical utility of PRS is still being evaluated, but what hasn't yet been evaluated is how to communicate such results to patients, and how they respond to their PRS scores.
Published 11/01/21
Polygenic risk scores (PRS) can be an important tool in breast cancer patients to help stratify individuals into levels of disease risk. The clinical utility of PRS is still being evaluated, but what hasn't yet been evaluated is how to communicate such results to patients, and how they respond to their PRS scores. On this month’s GenePod, Tatiane Yanes, a post-doctoral researcher at the University of Queensland and a genetic counselor at the Queensland Children’s Hospital, discusses how a...
Published 10/29/21
Published 10/15/21